Iktos has announced collaborative research with Zealand Pharma A/S, a biotechnology company specializing in innovative peptide-based medicines, to co-develop generative and predictive AI technologies for peptide drug design. Iktos is a company specializing in developing AI solutions applied to chemical research.
According to the agreement, Zealand Pharma will impart its expertise in peptide drug discovery to the generative modeling technologies, expertise in machine learning, and AI of Iktos.
In a statement, Iktos said that the company is looking forward to working with Zealand Pharma’s experienced R&D team to build leading peptide predictive and generative modeling technology in the field of peptides.
Iktos’ artificial intelligence technology is based on a unique data-driven chemical structure creation technology that brings new perspectives into the drug discovery procedure. The technology automatically designs virtual novel molecules with all the essential characteristics of an ideal drug molecule.
Iktos has recently diversified its R&D efforts into developing an AI technology for peptide-based therapeutics. The company has also developed superior predictive and generative models to assist the design of new peptide therapeutics with desired properties.
Zealand Pharma A/S has an excellent track record of inventing and developing novel peptide-based drugs. The complete has extensive experience in improving the therapeutic characteristics of peptides.
Zealand Pharma is focusing on expanding its computational chemistry toolbox to integrate artificial intelligence and machine learning-based procedures to design novel therapeutic peptides.
Yann Gaston-Mathé, President and CEO of Iktos, said that the company is pleased to have joined forces with Zealand Pharma. He added that the company expects to leverage Zealand Pharma’s extensive knowledge in peptide therapeutics with Iktos’ existing technology to initiate peptide drug discovery.